BiotechTube
Home/Endurance Bio/Andrew Lam
AL

Andrew Lam

Co-founder, Chief Technology Officer

Endurance Bio

Therapeutic Areas

Neurodegenerative DiseasesMetabolic DiseasesMuscle DisordersAging-related Diseases

Endurance Bio Pipeline

DrugIndicationPhase
T-168Neurodegenerative Diseases (ALS, Parkinson's, Alzheimer's)Phase 2
T-621Not Specified (Neurodegenerative, Metabolic, Muscle, Aging-related)Pre-clinical

Leadership Team at Endurance Bio

FG
Frederic Godderis
Founder, CEO, Director
EL
Enchi Liu
Co-founder, Chief Development Officer
SR
Saira Ramasastry
Corporate Development Lead
View full Endurance Bio profile